Bio-Rad Levels Charges Against Zeiss

A dispute over rights to multiphoton fluorescence excitation has emerged between Carl Zeiss GmbH of Jena, Germany, and Bio-Rad Laboratories Inc. in Hertfordshire, UK.

Bio-Rad says it signed a worldwide exclusive license with Cornell University's research foundation in 1996 to commercialize and market the technology. Since then, it has worked with the Ithaca, N.Y., university to develop the technology.





LATEST NEWS

• 3D Holography Integrated Glasses Could Unlock Mixed Reality
  May 2, 2024
• Generative AI Achieves Superresolution with Minimal Tuning
  May 2, 2024
• AmeriCOM Adds President and CEO: People in the News: 5/1/24
  May 1, 2024
• Machine Learning Pushes High-Power Lasing Limits
  May 1, 2024
• IPG Names Industry Veteran Mark Gitin CEO
  Apr 30, 2024
• 16th Biannual Optatec Conference Continues in Frankfurt
  Apr 30, 2024
• Celestial Surface Mapping Tech Combines Established Techniques
  Apr 30, 2024
• TSMC Partnerships Target Integrated Photonics Capabilities
  Apr 30, 2024